Medications Used in Trauma Treatment: What You Should Know

PTSD requires exposure to a qualifying traumatic event — actual or threatened death, serious injury, or sexual violence — either directly, witnessing it, learning it happened to a close other, or through repeated or extreme exposure to aversive details (as in first responders). The diagnostic criteria organize into four symptom clusters:

• Re-experiencing — intrusive memories, nightmares, dissociative flashbacks, psychological distress or physiological reactivity to trauma cues. The nervous system behaves as if the trauma is happening now, not in the past.
• Avoidance — deliberate efforts to avoid trauma-related thoughts, feelings, or external reminders (places, people, activities, situations). Avoidance provides temporary relief and long-term reinforcement of the trauma response.
• Negative alterations in cognition and mood — distorted blame of self or others, persistent negative emotional states, diminished interest in significant activities, feeling detached or estranged from others, inability to experience positive emotions. This cluster explains why PTSD often gets misdiagnosed as depression.
• Alterations in arousal and reactivity — hypervigilance, exaggerated startle response, sleep disturbance, irritability and angry outbursts, reckless behavior, difficulty concentrating. This is the hyperarousal cluster that makes daily functioning exhausting.

All four clusters must be present for at least one month and must cause clinically significant distress or functional impairment. The full constellation distinguishes PTSD from acute stress disorder, adjustment disorder, and the depressive episodes that can follow trauma exposure.

This is the most important thing to understand before we get into specific medications: trauma is a memory encoding and processing problem, not simply a neurochemical imbalance. What has happened in PTSD is that traumatic memories have been encoded differently from ordinary memories — they are stored with intense sensory detail, without the contextual framing that tells the nervous system “this happened in the past,” and without the extinction learning that normally allows a threatening memory to lose its physiological charge over time.

Medication can modulate the neurobiological symptoms of PTSD — the arousal, the sleep disruption, the hyperreactivity, the depression and anxiety overlay. What medication cannot do is process the traumatic memory. It cannot integrate the fragmented sensory-emotional material into a coherent narrative that the hippocampus can file as past rather than present. That processing requires specific therapies: most robustly, trauma- focused CBT (Cognitive Processing Therapy or Prolonged Exposure) and EMDR.

As of this writing, only two medications carry FDA approval specifically for PTSD: sertraline (Zoloft) and paroxetine (Paxil). Both are SSRIs — selective serotonin reuptake inhibitors.

Sertraline (Zoloft)

Sertraline received FDA approval for PTSD in 1999, based on two large randomized controlled trials that showed significant improvement across all four PTSD symptom clusters compared to placebo. The typical effective dose range is 50–200 mg/day. The onset of therapeutic effect in PTSD — as with depression and anxiety — is gradual, typically 4–8 weeks for meaningful symptom reduction. Initial side effects (GI upset, insomnia, transient increase in anxiety) are common in the first 1–2 weeks and generally resolve.

Paroxetine (Paxil)

Paroxetine received FDA approval for PTSD in 2001. It is also an SSRI, but with additional anticholinergic and antihistaminergic activity that makes it more sedating than sertraline — which can be useful in patients with severe hyperarousal and insomnia, but problematic for those who experience cognitive side effects or weight gain. The typical dose range is 20–60 mg/day. Paroxetine also has a notably shorter half-life than other SSRIs, which means discontinuation syndrome (dizziness, “brain zaps,” nausea, irritability) is more likely if doses are missed or the medication is stopped abruptly.

Response rates for the FDA-approved SSRIs in PTSD are meaningful but not dramatic: approximately 60% of patients achieve a response (≥30% symptom reduction), and full remission rates are lower than in depression or panic disorder. This is important context — PTSD is a condition in which medication provides partial, not complete, relief, even with the approved agents.

“Off-label” means a medication is being used for a condition, dose, or population outside the specific parameters in its FDA approval — it does not mean experimental, unproven, or unsafe. The FDA approves medications; it does not regulate the practice of medicine. Prescribers can and routinely do prescribe medications off-label when the evidence supports clinical benefit.

In PTSD, some of the most important medications in clinical practice are used off-label because the FDA approval process is expensive, long, and driven primarily by pharmaceutical industry investment — not by clinical need. Several off-label options have substantial evidence and are widely used in clinical practice.

Prazosin is an alpha-1 adrenergic receptor blocker originally developed as an antihypertensive. Its use in PTSD nightmares is one of the more elegant examples of mechanism-driven pharmacotherapy in psychiatry.

The neurobiological rationale: trauma nightmares are driven in part by elevated noradrenergic activity during REM sleep. The locus coeruleus — the brain's primary norepinephrine production center — shows heightened activity in PTSD, which is amplified during sleep. This drives the re-experiencing of trauma content during REM. Prazosin blocks the alpha-1 receptor in the brain, dampening noradrenergic signaling specifically in the circuits involved in the fear and arousal response during sleep.

Murray Raskind, a psychiatrist at the University of Washington, pioneered the research on prazosin in PTSD nightmares over nearly two decades. His early trials showed striking reductions in trauma nightmare frequency and intensity, improved sleep quality, and reduction in daytime hyperarousal. The mechanism is specific enough that some patients describe a notable change within 1–2 weeks of initiation.

The clinical picture is more nuanced than early trials suggested. A 2018 VA cooperative study (the largest randomized controlled trial of prazosin in PTSD to date) did not show benefit over placebo in the primary outcome — but subgroup analyses and clinical experience suggest it remains valuable in selected patients, particularly those with prominent nightmare symptoms. Typical doses are 1–15 mg at bedtime. The main side effects are orthostatic hypotension (dizziness on standing), which is why dosing starts low and is titrated slowly.

Venlafaxine (Effexor) is an SNRI — a serotonin-norepinephrine reuptake inhibitor — with randomized controlled trial evidence for PTSD that is comparable to the FDA-approved SSRIs, though it has not pursued the FDA indication. The dual mechanism (serotonin and norepinephrine) may offer advantages in patients whose PTSD is accompanied by prominent hyperarousal, concentration difficulty, or pain symptoms.

VA and Department of Defense clinical practice guidelines include venlafaxine as a recommended first-line pharmacotherapy for PTSD alongside sertraline and paroxetine — a de facto recognition that the evidence base is equivalent even without FDA approval. Typical therapeutic doses are 150–225 mg/day. Venlafaxine shares paroxetine's risk of discontinuation syndrome (its short half-life means missed doses produce symptoms quickly), which requires patient education.

For patients who have a partial response to first-line SSRIs or SNRIs, augmentation with low-dose atypical antipsychotics is a recognized clinical strategy — particularly when hyperarousal, sleep disruption, and anger/irritability remain prominent after an adequate SSRI trial.

Quetiapine (Seroquel)

Quetiapine at low doses (25–100 mg at bedtime) has evidence as monotherapy and augmentation in PTSD. Its combination of H1 antihistamine blockade (strongly sedating), alpha-1 adrenergic blockade (reduces arousal), and D2/5-HT2A modulation addresses multiple symptom dimensions simultaneously. The primary concerns are metabolic — weight gain, glucose dysregulation, and lipid changes — which require ongoing monitoring and informed consent. Quetiapine is not a benign sleep aid; it is an antipsychotic with real metabolic risks that must be weighed against benefit.

Risperidone (Risperdal)

Risperidone augmentation has a randomized controlled trial evidence base in PTSD, particularly for re-experiencing symptoms and hyperarousal. A meta-analysis of augmentation studies showed significant reduction in PTSD severity with risperidone added to SSRI treatment. The side effect profile — EPS (movement-related side effects), weight gain, metabolic effects, and prolactin elevation — means it is generally reserved for patients with significant residual symptoms after first-line treatment.

This section is among the most important in this guide, because benzodiazepines — lorazepam, clonazepam, alprazolam, diazepam — are still commonly prescribed for PTSD despite mounting evidence that they may worsen outcomes.

The clinical problem is layered:

Fear Conditioning Interference

Trauma recovery requires extinction learning — the gradual process by which the nervous system learns that the trauma-associated stimulus is no longer dangerous. This learning depends on the brain experiencing the stimulus (or a cue of it) without the catastrophic outcome, allowing new learning to override the conditioned fear response. Benzodiazepines blunt the anxiety signal that extinction depends on. If the medication prevents the person from fully experiencing the anxiety when confronting trauma cues, the extinction learning cannot occur. The result is not healing; it is temporary suppression followed by unchanged (or worsened) fear conditioning.

Dissociation Risk

PTSD frequently co-occurs with dissociative symptoms. Benzodiazepines, which are GABA-A positive allosteric modulators, can worsen dissociation in vulnerable individuals — producing an experience of emotional numbness and derealization that feels like relief in the short term but worsens the disconnection from affect that trauma treatment needs to address.

Evidence of Worse Outcomes

Several retrospective and prospective studies have found that benzodiazepine use in the acute post-trauma period is associated with higher rates of PTSD development and worse long-term outcomes. VA/DoD clinical practice guidelines explicitly recommend against benzodiazepines for PTSD. The APA PTSD practice guideline notes that while benzodiazepines may provide short-term symptomatic relief, the overall evidence does not support their use.

Phenelzine, a monoamine oxidase inhibitor (MAOI), has genuine evidence in PTSD — several randomized controlled trials from the 1980s and 1990s showed significant symptom reduction across all four PTSD clusters, particularly in re-experiencing symptoms. MAOIs are not first-line in current practice for important practical reasons: they require a tyramine-restricted diet to prevent hypertensive crisis, they have significant drug-drug interactions (including fatal serotonin syndrome with SSRIs and many common medications), and they cannot be started for 2 weeks after stopping an SSRI (or 5 weeks after stopping fluoxetine).

For patients with PTSD who have failed multiple first- and second-line treatments, phenelzine remains a clinically legitimate option — particularly in individuals who can reliably follow the dietary and drug restrictions. This is typically a specialist-level conversation.

The intersection of trauma with dissociation is clinically significant from a pharmacotherapy perspective. Patients who experience significant dissociation alongside PTSD symptoms often have more attenuated responses to first-line SSRIs and may be more sensitive to medication side effects. This is not well understood mechanistically, but it has clinical implications:

• Dissociation may need to be addressed in therapy before medication response can be optimized — because dissociation during therapy prevents the emotional processing that medication is supposed to support
• Some clinicians believe that treating dissociation first (through stabilization-phase trauma therapy) and then addressing the PTSD proper produces better medication outcomes
• For patients with comorbid PTSD and dissociative disorder, the choice of augmentation strategy should take into account the risk of worsening dissociation — which argues against benzodiazepines and, in some presentations, sedating antihistaminergic medications

The clearest statement in any PTSD treatment guideline is this: trauma-focused psychotherapy is the first-line treatment for PTSD. Not because medication is ineffective, but because the evidence for trauma-focused therapy is stronger, more durable, and more likely to produce full remission.

Cognitive Processing Therapy (CPT)

CPT is a structured 12-session protocol that addresses the “stuck points” — the specific beliefs about the trauma, the self, and the world that have become rigidly held and are interfering with recovery. It involves a combination of written accounts of the trauma and structured cognitive worksheets targeting the beliefs that are maintaining PTSD. Large randomized controlled trials show CPT produces significant, sustained PTSD symptom reduction and full remission in a substantial proportion of patients.

EMDR (Eye Movement Desensitization and Reprocessing)

EMDR involves guided bilateral stimulation (typically eye movements, though also tapping or auditory tones) while the patient focuses on traumatic memories. The mechanism is not fully established, but the working hypothesis is that the bilateral stimulation mimics the eye movement patterns of REM sleep, facilitating the adaptive processing of traumatic memory in a way that allows it to be integrated rather than re-experienced. The evidence base is robust — EMDR has WHO and VA/DoD endorsement as first-line treatment for PTSD.

One of the most common barriers to seeking psychiatric care after trauma is the expectation that you will have to tell the whole story in detail. You do not. A competent prescriber can work with you effectively without hearing the complete narrative of what happened. Here is language that allows you to share what clinically matters without re-traumatizing yourself:

• “I've been through a traumatic experience that I'm not ready to describe in detail. I want to talk about the symptoms I'm having — nightmares, hypervigilance, avoiding certain situations — and what medication options might help with those.”
• “The trauma happened [approximate timeframe]. I'm in therapy with a [EMDR/CPT/trauma-focused] therapist. I'm looking for medication support to help me be able to engage in the therapy.”
• “I've been told I might have PTSD. My main symptoms are [nightmares / hypervigilance / avoiding certain places / emotional numbness / angry outbursts]. I'd like to understand my options.”
• “I want to understand what role medication plays in trauma treatment — and I specifically want to know whether benzodiazepines are recommended, because I've read they may not be.”

A prescriber who responds to that last question dismissively — or who prescribes benzodiazepines without discussing the evidence — is one worth getting a second opinion from.